Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at udforske effektiviteten af ​​JNJ-89495120 i behandlingen af ​​svær depressiv lidelse (Moonlight-1)

24. september 2026 opdateret af: Janssen Research & Development, LLC

En randomiseret, dobbeltblind, multicenter, placebokontrolleret, Proof-of-Concept-undersøgelse til evaluering af effektiviteten, sikkerheden og tolerabiliteten af ​​JNJ-89495120 som monoterapi hos voksne deltagere med svær depressiv lidelse (MDD)

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).

Studieoversigt

Status

Afsluttet

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

105

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Huntsville, Alabama, Forenede Stater, 35801
        • UAB Huntsville Regional Medical Campus
    • Arizona
      • Chandler, Arizona, Forenede Stater, 85224
        • Chandler Clinical Trials
      • Phoenix, Arizona, Forenede Stater, 85012
        • IMA Clinical Research PC Phoenix
      • Tucson, Arizona, Forenede Stater, 85724
        • University of Arizona
      • Tucson, Arizona, Forenede Stater, 85704
        • Noble Clinical Research
    • California
      • Bellflower, California, Forenede Stater, 90706
        • CI Trials
      • Encino, California, Forenede Stater, 91316
        • Wake Research PRI Encino
      • Garden Grove, California, Forenede Stater, 92844
        • National Institute Of Clinical Research
      • Newport Beach, California, Forenede Stater, 92660
        • WR-Newport Beach
      • Orange, California, Forenede Stater, 92866
        • ATP Clinical Research
      • Redlands, California, Forenede Stater, 92374
        • Anderson Clinical Research
      • San Diego, California, Forenede Stater, 92103
        • Artemis Institute for Clinical Research
      • San Jose, California, Forenede Stater, 95124
        • Lumos Clinical Research Center LLC
      • Santa Ana, California, Forenede Stater, 92705
        • Syrentis Clinical Research
      • Temecula, California, Forenede Stater, 92591
        • Inland Psychiatric Medical Group Inc
      • Walnut Creek, California, Forenede Stater, 94596
        • Sunwise Clinical Research
    • Colorado
      • Denver, Colorado, Forenede Stater, 80209
        • Mountain View Clinical Research
    • Florida
      • Fort Myers, Florida, Forenede Stater, 33912
        • Gulfcoast Medical Research Center
      • Hollywood, Florida, Forenede Stater, 33021
        • The Medici Medical Research
      • Homestead, Florida, Forenede Stater, 33030
        • Advanced Research Institute of Miami
      • Maitland, Florida, Forenede Stater, 32751
        • K2 Medical Research
      • Miami, Florida, Forenede Stater, 33126
        • Pharmax Research Clinic Inc
      • Miami, Florida, Forenede Stater, 33135
        • Wellness Research Center
      • Pembroke Pines, Florida, Forenede Stater, 33024
        • Best Choice Medical and Research Service
      • Tampa, Florida, Forenede Stater, 33629
        • Interventional Psychiatry of Tampa Bay
      • West Palm Beach, Florida, Forenede Stater, 33407
        • Health Synergy Clinical Research
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30328
        • Synexus Clinical Research US Inc
      • Decatur, Georgia, Forenede Stater, 30030
        • iResearch Atlanta LLC
      • Snellville, Georgia, Forenede Stater, 30078
        • Accelerated Clinical Research Group LLC
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • University of Chicago Medical Center
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Indiana University IU Health
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70115
        • DelRicht Research
    • Maryland
      • Gaithersburg, Maryland, Forenede Stater, 20877
        • CBH Health
    • Massachusetts
      • Worcester, Massachusetts, Forenede Stater, 01655
        • University of Massachusetts Medical School
    • New York
      • Brooklyn, New York, Forenede Stater, 11229
        • Integrative Clinical Trials LLC
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45219
        • University of Cincinnati
      • Cincinnati, Ohio, Forenede Stater, 45215
        • Patient Priority Clinical Sites LLC
      • Columbus, Ohio, Forenede Stater, 43210
        • OSU Department of Psychiatry and Behavioral Health
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73116
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • University of Pennsylvania
    • South Carolina
      • North Charleston, South Carolina, Forenede Stater, 29405
        • Coastal Carolina Research Center
    • Texas
      • McKinney, Texas, Forenede Stater, 75071
        • Revival Research Institute LLC
    • Utah
      • Clinton, Utah, Forenede Stater, 84015
        • Alpine Research Organization
    • Washington
      • Everett, Washington, Forenede Stater, 98201
        • Core Clinical Research

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 64 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
  • Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
  • Were first diagnosed with depression before the age of 55
  • Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
  • Have taken 0, 1, or 2 treatments for depression in your current episode
  • Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening

Exclusion Criteria:

  • Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
  • Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
  • Post-traumatic stress disorder within the past three years of screening
  • Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
  • History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
  • Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm 1: JNJ-89495120 Dose A

Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study.

JNJ-89495120 will be administered.

Eksperimentel: Arm 2: JNJ-89495120 Dose A and Dose B

Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study.

JNJ-89495120 will be administered.

Placebo komparator: Arm 3: Placebo Group

Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study.

Placebo will be administered.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
Tidsramme: Baseline up to Day 5

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 5

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline in MADRS Total Score to Day 2
Tidsramme: Baseline up to Day 2

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 2
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
Tidsramme: Baseline up to Day 2 and Day 5

The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity.

Baseline up to Day 2 and Day 5
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
Tidsramme: Baseline up to Day 5

The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology.

Baseline up to Day 5
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
Tidsramme: Baseline up to Day 5

The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21).

Baseline up to Day 5
Number of Participants with Adverse Events (AEs)
Tidsramme: Up to approximately 18 weeks

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to approximately 18 weeks
Number of Participants with Abnormalities in Vital Signs Parameters
Tidsramme: Up to approximately 18 weeks

Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported.

Up to approximately 18 weeks
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Tidsramme: Up to approximately 18 weeks

Participants with 12-lead ECG abnormalities will be reported.

Up to approximately 18 weeks
Number of Participants With Abnormalities in Laboratory Parameters
Tidsramme: Up to approximately 18 weeks

Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported.

Up to approximately 18 weeks
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
Tidsramme: Up to approximately 18 weeks

Participants with changes in weight/BMI will be reported.

Up to approximately 18 weeks
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
Tidsramme: Up to approximately 18 weeks

The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

Up to approximately 18 weeks
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
Tidsramme: From Baseline up to 4 weeks

The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials.

From Baseline up to 4 weeks
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
Tidsramme: From Baseline up to 4 weeks

The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds.

From Baseline up to 4 weeks
Plasma Concentrations of JNJ-89495120
Tidsramme: Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Plasma concentrations of JNJ-89495120 will be reported.

Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. december 2024

Primær færdiggørelse (Faktiske)

25. juni 2026

Studieafslutning (Faktiske)

10. august 2026

Datoer for studieregistrering

Først indsendt

15. januar 2025

Først indsendt, der opfyldte QC-kriterier

15. januar 2025

Først opslået (Faktiske)

20. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

24. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 89495120MDD2001
  • 89495120MDD2001 (Anden identifikator: Janssen Research & Development, LLC)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner